| Literature DB >> 20946631 |
Joerg Krebs1, Paolo Pelosi, Charalambos Tsagogiorgas, Liesa Zoeller, Patricia R M Rocco, Benito Yard, Thomas Luecke.
Abstract
INTRODUCTION: To test the hypothesis that open lung (OL) ventilatory strategies using high-frequency oscillatory ventilation (HFOV) or controlled mechanical ventilation (CMV) compared to CMV with lower positive end-expiratory pressure (PEEP) improve respiratory function while minimizing lung injury as well as systemic inflammation, a prospective randomized study was performed at a university animal laboratory using three different lung conditions.Entities:
Mesh:
Year: 2010 PMID: 20946631 PMCID: PMC3219289 DOI: 10.1186/cc9291
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Schematic flow chart of the study design. UI, uninjured; SW, lung injury induced by saline washout; LPS, lung injury induced by intraperitoneal/intravenous Escherichia coli lipopolysaccharide; BL, baseline measurements; RM/PT, recruitment manoeuvre followed by decremental positive end-expiratory pressure (PEEP) trial; LP-CMV, controlled mechanical ventilation (CMV) with low PEEP; BP-CMV, controlled mechanical ventilation (CMV) with "best" PEEP; HFOV, high-frequency oscillatory ventilation.
Baseline parameters
| UI | SW | LPS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| LP-CMV | BP-CMV | HFOV | LP-CMV | BP-CMV | HFOV | LP-CMV | BP-CMV | HFOV | |
| Pinsp | 11.8 ± 1.0 | 12.8 ± 2.0 | 12.4 ± 0.9 | 26.1 ± 2.0 | 25.6 ± 1.3 | 27.0 ± 2.5 | 11.2 ± 0.9 | 10,5 ± 0.8 | 11.3 ± 0.5 |
| Estat,RS | 2.7 ± 0.5 | 2.7 ± 0.5 | 2.8 ± 0.3 | 6.4 ± 1.1 | 6.3 ± 0.7 | 6.8 ± 1.1 | 2.9 ± 0.3 | 2.8 ± 0.4 | 3.0 ± 0.4 |
| PaO2/FiO2 | 504.0 ± 17.4 | 481.5 ± 44.7 | 482.8 ± 70.6 | 73.1 ± 19.9 | 76.8 ± 17.9 | 78.0 ± 13.7 | 477.2 ± 48.6 | 428.5 ± 80.1 | 458.4 ± 33.3 |
| PaCO2 | 46.2 ± 5.3 | 39.2 ± 8.0 | 46.8 ± 5.7 | 56.6 ± 7.2 | 63.0 ± 7.2 | 53.8 ± 10.1 | 45.0 ± 8.2 | 44.7 ± 15.7 | 49.0 ± 8.1 |
UI, uninjured; SW, lung injury induced by saline washout; LPS, lung injury induced by intraperitoneal/intravenous E. coli lipopolysaccharide; BL, baseline measurements; LP-CMV, controlled mechanical ventilation with low PEEP; BP-CMV, controlled mechanical ventilation with "best" PEEP; HFOV, high frequency oscillatory ventilation; Pinsp, End-inspiratory plateau pressures at baseline; Estat, RS, Respiratory system elastance (Estat, RS) at baseline; PaO2/FiO2, PaO2/FiO2 index at baseline; PaCO2, PaCO2 at baseline. Values are means ± standard deviation. No significant differences were noted in the respective treatment groups at baseline. UI, uninjured; SW, lung injury induced by saline washout; LPS, lung injury induced by intraperitoneal/intravenous E. coli lipopolysaccharide.
Figure 2End-inspiratory plateau pressures after 6 hours of mechanical ventilation. Black bars represent the level of PEEP. Values are means ± SEM of eight animals in each group.
Figure 3Respiratory system elastance (E. Values are means ± SEM of eight animals in each group.
Figure 4PaO. Values are means ± SEM of eight animals in each group.
Figure 5PaCO. Values are means ± SEM of eight animals in each group.
Figure 6Histological total lung injury score. Boxes show interquartile (25%-75%) range, whiskers encompass range and horizontal lines represent median value.
Histological lung injury score
| UI | SW | LPS | ||
|---|---|---|---|---|
| Haemorrhage | LP-CMV | 0.0 (0.0/0.0) | 0.0 (0.0/0.0) | 2.0 (1.0/3.0) |
| BP-CMV | 0.0 (0.0/0.0) | 1.0 (0.0/1.0) | 1.0 (1.0/3.0) | |
| HFOV | 0.0 (0.0/0.0) | 1.0 (0.0/1.5) | 2.0 (1.0/2.0) | |
| Inflammation | LP-CMV | 1.0 (0.0/2.0) | 2.0 (2.0/3.0) | 4.0 (4.0/4.0)a,b |
| BP-CMV | 1.0 (0.75/1.0) | 1.0 (1.0/2.0) | 3.0 (3.0/4.0) | |
| HFOV | 1.0 (0.0/1.25) | 2.0 (1.0/2.0) | 3.0 (3.0/4.0) | |
| Oedema | LP-CMV | 0.0 (0.0/0.0) | 3.0 (2.5/4.0)a,b | 2.0 (1.0/2.0) |
| BP-CMV | 0.0 (0.0/0.0) | 0.0 (0.0/2.0) | 2.0 (0.0/2.0) | |
| HFOV | 0.0 (0.0/0.0) | 0.0 (0.0/0.0) | 1.0 (0.0/2.0) | |
| Atelectasis | LP-CMV | 2.5 (1.5/3.25)b | 2.0 (1.0/2.0) | 2.5 (2.0/3.75)a |
| BP-CMV | 1.0 (1.0/2.0)c | 2.0 (1.0/2.5) | 1.0 (0.0/2.0) | |
| HFOV | 0.0 (0.0/1.0) | 1.0 (0.5/1.5) | 1.0 (1.0/2.0) | |
| Overinflation | LP-CMV | 0.0 (0.0/1.5)a,b | 2.0 (2.0/3.0) | 1.0 (0.25/1.75) |
| BP-CMV | 2.0 (1.75/3.25) | 1.0 (1.0/2.0) | 2.0 (1.0/2.0) | |
| HFOV | 2.0 (1.75/2.5) | 2.0 (1.5/3.5) | 3.0 (1.0/3.0) | |
| Total lung injury score (sum) | LP-CMV | 4.0 (3.75/5.0) | 10.0 (9.0/11.0)a,b | 12 (10.25/13.0)a |
| BP-CMV | 4.5 (3.0/6.0) | 7.0 (5.5/7.5) | 10.0 (8.0/10.0) | |
| HFOV | 3.5 (2.0/5.0) | 6.0 (5.0/6.0) | 10.0 (9.0/11.0) |
Baseline measurements; LP-CMV, controlled mechanical with low PEEP; BP-CMV, controlled mechanical ventilation with "best" PEEP; HFOV, high-frequency oscillatory ventilation. Values are medians and interquartile (25%-75%) range. aP < 0.05 LP-CMV vs. BP-CMV. bP < 0.05 LP-CMV vs. HFOV. cP < 0.05 BP-CMV vs. HFOV.
Lung inflammatory and fibrotic response
| UI | SW | LPS | ||
|---|---|---|---|---|
| TNF-α | LP-CMV | 5.9 (4.6/7.8) | 2.3 (1.9/2.9) | 13.1 (12.2/15.5) |
| BP-CMV | 6.0 (4.9/7.4) | 2.8 (2.9/3.0) | 21.1 (12.8/24.1)c | |
| HFOV | 6.5 (3.7/7.4) | 3.5 (1.8/4.0) | 12.7 (11.6/15.6) | |
| Interleukin-1β | LP-CMV | 6.4 (4.6/7.5) | 2.9 (2.4/6.1)a,b | 8.4 (7.6/9.9) |
| BP-CMV | 4.5 (3.5/6.6) | 2.2 (1.5/3.0)* | 10.4 (8.3/11.1 | |
| HFOV | 4.3 (3.7/5.9) | 2.2 (1.8/3.2)* | 9.5 (8.4/11.2) | |
| Interleukin-6 | LP-CMV | 24.0 (10.2/30.5) | 625.2 (399.8/880.0)a,b | 1278.5 (1187.4/1390.2)a,b |
| BP-CMV | 16.0 (6.7/23.7) | 380.7 (205.4/417.5) | 498.4 (381.2/568.2) | |
| HFOV | 5.7 (3.6/14.7) | 367.4 (182.9/496.1) | 446.1 (252.6/563.8) | |
| Procollagen I | LP-CMV | 1.0 (0.8/1.2)*a | 0.5 (0.6/0.8)* | 0.4 (0.3/0.4) |
| BP-CMV | 1.4 (1.1/2.0)c | 0.6 (0.5/1.2)* | 0.2 (0.1/0.4) | |
| HFOV* | 1.0 (0.7/1.5)* | 0.8 (0.4/1.0)* | 0.3 (0.3/0.5) | |
| Procollagen III | LP-CMV | 0.5 (0.5/0.6) | 0.3 (0.2/0.4) | 0.2 (0.1/0.2) |
| BP-CMV | 0.6 (0.5/0.8) | 0.3 (0.2/0.3) | 0.2 (0.1/0.3) | |
| HFOV | 0.5 (0.4/0.6) | 0.3 (0.2/0.3) | 0.2 (0.2/0.3) |
UI, uninjured; SW, lung injury induced by saline washout; LPS, lung injury induced by intraperitoneal/intravenous E. coli lipopolysaccharide; LP-CMV, controlled mechanical ventilation with low PEEP; BP-CMV, controlled mechanical ventilation with "best" PEEP; HFOV, high frequency oscillatory ventilation. Values are medians and interquartile (25%-75%) range and are presented as fold changes relative to unventilated control group. *P > 0.05 vs. unventilated control group. aP < 0.05 LP-CMV vs. BP-CMV. bP < 0.05 LP-CMV vs. HFOV. cP < 0.05 BP-CMV vs. HFOV.
Systemic inflammatory response
| Control | UI | SW | LPS | ||
|---|---|---|---|---|---|
| TNF-α (pg/ml) | 0 (0/0) | LP-CMV | 18.0 (15.0/29.0) | 0 (0/17.75)* | 52.0 (45.0/136.5) |
| BP-CMV | 49.0 (20.0/55.5)c | 0 (0/0)* | 34.0 (26.25/48.75) | ||
| HFOV | 9.0 (9.0/16.5) | 0 (0/0)* | 29.5 (27.0/39.25) | ||
| Interleukin-1β (pg/ml) | 19.5 (15.5/24.25) | LP-CMV | 17.5 (15.0/24.25)b | 11.5 (0/26.25) | 51.0 (47.0/117.0)b |
| BP-CMV | 16.5 (15.0/34.5)c | 0 (0/5.5) | 46.0 (36.0/265.25)c | ||
| HFOV | 0 (0/0) | 6 (0/6.25) | 31.5 (23.5/33.25) | ||
| Interleukin-6 (pg/ml) | 41.0 (34.0/48.0) | LP-CMV | 232.0 (187.0/290.0)b | 185.0 (149.0/218.0)a | 22320.0 (16375.0/65440.0) |
| BP-CMV | 262.0 (232.0/276.0)c | 53.0 (40.0/127.5) | 14395.0 (9300.0/54967.5) | ||
| HFOV | 78.0 (55.0/145.5) | 169.0 (95.5/239.0) | 35930.0 (20090.0/43025.0) |
UI, uninjured; SW, lung injury induced by saline washout; LPS, lung injury induced by intraperitoneal/intravenous E. coli lipopolysaccharide; BL, baseline measurements; LP-CMV, controlled mechanical ventilation with low PEEP; BP-CMV, controlled mechanical ventilation with "best" PEEP; HFOV, high frequency oscillatory ventilation. Values are medians and interquartile (25%-75%) range. aP < 0.05 LP-CMV vs. BP-CMV. bP < 0.05 LP-CMV vs. HFOV. cP < 0.05 BP-CMV vs. HFOV.